BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

755 related articles for article (PubMed ID: 25138991)

  • 1. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody.
    Pardridge WM
    Expert Opin Drug Deliv; 2015 Feb; 12(2):207-22. PubMed ID: 25138991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse.
    Boado RJ; Zhang Y; Wang Y; Pardridge WM
    Biotechnol Bioeng; 2009 Mar; 102(4):1251-8. PubMed ID: 18942151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
    Pardridge WM; Boado RJ
    Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Pharmacokinetics of High-Affinity Transferrin Receptor Antibody-Erythropoietin Fusion Protein is a Function of Effector Attenuation in Mice.
    Sun J; Boado RJ; Pardridge WM; Sumbria RK
    Mol Pharm; 2019 Aug; 16(8):3534-3543. PubMed ID: 31199881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein.
    Zhou QH; Lu JZ; Hui EK; Boado RJ; Pardridge WM
    Bioconjug Chem; 2011 Aug; 22(8):1611-8. PubMed ID: 21707084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor.
    Boado RJ; Zhou QH; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2010 Feb; 7(1):237-44. PubMed ID: 19921848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology.
    Pardridge WM
    BioDrugs; 2017 Dec; 31(6):503-519. PubMed ID: 29067674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
    Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain-penetrating tumor necrosis factor decoy receptor in the mouse.
    Zhou QH; Boado RJ; Hui EK; Lu JZ; Pardridge WM
    Drug Metab Dispos; 2011 Jan; 39(1):71-6. PubMed ID: 20884844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eliminating Fc N-Linked Glycosylation and Its Impact on Dosing Consideration for a Transferrin Receptor Antibody-Erythropoietin Fusion Protein in Mice.
    Yang J; Sun J; Castellanos DM; Pardridge WM; Sumbria RK
    Mol Pharm; 2020 Aug; 17(8):2831-2839. PubMed ID: 32579360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease.
    Chang R; Knox J; Chang J; Derbedrossian A; Vasilevko V; Cribbs D; Boado RJ; Pardridge WM; Sumbria RK
    Mol Pharm; 2017 Jul; 14(7):2340-2349. PubMed ID: 28514851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses.
    Pardridge WM
    Bioconjug Chem; 2008 Jul; 19(7):1327-38. PubMed ID: 18547095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies.
    Zhou QH; Boado RJ; Pardridge WM
    J Drug Target; 2012 Sep; 20(8):715-9. PubMed ID: 22845843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey.
    Boado RJ; Hui EK; Lu JZ; Sumbria RK; Pardridge WM
    Bioconjug Chem; 2013 Oct; 24(10):1741-9. PubMed ID: 24059813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins.
    Pardridge WM
    Adv Drug Deliv Rev; 2022 May; 184():114234. PubMed ID: 35307484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies.
    Pardridge WM
    Expert Opin Biol Ther; 2016 Dec; 16(12):1455-1468. PubMed ID: 27572805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgG Fusion Proteins for Brain Delivery of Biologics via Blood-Brain Barrier Receptor-Mediated Transport.
    Boado RJ
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor.
    Pardridge WM; Boado RJ; Patrick DJ; Ka-Wai Hui E; Lu JZ
    Mol Pharm; 2018 Nov; 15(11):5207-5216. PubMed ID: 30226787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biopharmaceutical drug targeting to the brain.
    Pardridge WM
    J Drug Target; 2010 Apr; 18(3):157-67. PubMed ID: 20064077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug targeting to the brain.
    Pardridge WM
    Pharm Res; 2007 Sep; 24(9):1733-44. PubMed ID: 17554607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.